COX 2 inhibitor

1 article · search the full text for this term

• Published Subscription 12 Jan 2024

  Design And Evaluation Of Meloxicam Tablet For Colon Cancer

  By Archana S, Dr Ibrahim Afsal V .T, Fathima Musthafal, Fathima PM, Ayisha Shafrin, Syamprasad PS

  Abstract: Meloxicam, recognized as a preferential COX-2 inhibitor, has emerged as a promising chemopreventive agent for colorectal cancer. Leveraging its local and targeted action on the colon, Meloxicam proves to be a formidable component in the prevention of colorectal malignancies. This study aims to innovate by formulating and evaluating a targeted tablet delivery system for Meloxicam, emphasizing site-specific and instant drug release in the colon, thereby maximizing its therapeutic efficacy in …

  Published in Research & Reviews: A Journal of Drug Design & Discovery · Vol. 10, Issue 3, 2023 · pp. 1–7 Read article →